NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$63.16|
|52 Week High||US$43.11|
|52 Week Low||US$72.61|
|1 Month Change||5.34%|
|3 Month Change||-8.52%|
|1 Year Change||28.35%|
|3 Year Change||-11.02%|
|5 Year Change||-5.25%|
|Change since IPO||454.04%|
Recent News & Updates
At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?
NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it saw significant share price movement...
NuVasive Still Getting No Love With COVID-19 And Competitive Worries
NuVasive produced its second straight quarter with a double-digit operating income beat, but in-line guidance and fears of renewed COVID-19 lockdowns seem to be weighing on the shares. New product innovation appears to be driving revenue growth, with Modulus and the cervical portfolio performing well, and Pulse about to launch. COVID-19 remains a clear short-term risk, but I believe NuVasive's opportunity to regain share and drive operating leverage is undervalued today.
|NUVA||US Medical Equipment||US Market|
Return vs Industry: NUVA underperformed the US Medical Equipment industry which returned 36.8% over the past year.
Return vs Market: NUVA underperformed the US Market which returned 35.3% over the past year.
Stable Share Price: NUVA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: NUVA's weekly volatility (4%) has been stable over the past year.
About the Company
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. it provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology and its intraoperative neuromonitoring services and support; and specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone. The company also offers reline fixation system that facilitates the preservation and restoration of patient alignment; integrated global alignment platform consisting of Bendini spinal rod bending system that assists with manual rod manipulation for spinal fixation; Lessray that is an image enhancement platform designed to reduce radiation exposure in the operating room, as well as Pulse, which integrates multiple enabling technologies to enhance workflow, reduce variability, and increase the reproducibility of surgical outcomes; and various biologics that are used to aid in the spinal fusion or bone healing process.
NuVasive Fundamentals Summary
|NUVA fundamental statistics|
Is NUVA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NUVA income statement (TTM)|
|Cost of Revenue||US$319.35m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.036|
|Net Profit Margin||0.16%|
How did NUVA perform over the long term?See historical performance and comparison
Is NuVasive undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NUVA ($63.16) is trading below our estimate of fair value ($69.32)
Significantly Below Fair Value: NUVA is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: NUVA is poor value based on its PE Ratio (1761.3x) compared to the US Medical Equipment industry average (52.3x).
PE vs Market: NUVA is poor value based on its PE Ratio (1761.3x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: NUVA is poor value based on its PEG Ratio (44.6x)
Price to Book Ratio
PB vs Industry: NUVA is good value based on its PB Ratio (3.9x) compared to the US Medical Equipment industry average (4.8x).
How is NuVasive forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NUVA's forecast earnings growth (39.5% per year) is above the savings rate (2%).
Earnings vs Market: NUVA's earnings (39.5% per year) are forecast to grow faster than the US market (15% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NUVA's revenue (7.3% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: NUVA's revenue (7.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NUVA's Return on Equity is forecast to be low in 3 years time (15.4%).
How has NuVasive performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NUVA has a large one-off loss of $25.3M impacting its June 30 2021 financial results.
Growing Profit Margin: NUVA became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: NUVA's earnings have declined by 33% per year over the past 5 years.
Accelerating Growth: NUVA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NUVA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (40.5%).
Return on Equity
High ROE: NUVA's Return on Equity (0.2%) is considered low.
How is NuVasive's financial position?
Financial Position Analysis
Short Term Liabilities: NUVA's short term assets ($765.7M) exceed its short term liabilities ($193.7M).
Long Term Liabilities: NUVA's short term assets ($765.7M) do not cover its long term liabilities ($1.1B).
Debt to Equity History and Analysis
Debt Level: NUVA's debt to equity ratio (104.8%) is considered high.
Reducing Debt: NUVA's debt to equity ratio has increased from 95.3% to 104.8% over the past 5 years.
Debt Coverage: NUVA's debt is well covered by operating cash flow (26.3%).
Interest Coverage: NUVA's interest payments on its debt are not well covered by EBIT (1.8x coverage).
What is NuVasive current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NUVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NUVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NUVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NUVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NUVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Barry (48 yo)
Mr. J. Christopher Barry, also known as Chris, serves as Chief Executive Officer and Director of NuVasive, Inc., since November 5, 218. Mr. Barry served commercial and leadership roles at Covidien. He has...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD4.82M) is about average for companies of similar size in the US market ($USD5.28M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
Experienced Management: NUVA's management team is considered experienced (2.8 years average tenure).
Experienced Board: NUVA's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
NuVasive, Inc.'s employee growth, exchange listings and data sources
- Name: NuVasive, Inc.
- Ticker: NUVA
- Exchange: NasdaqGS
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$3.263b
- Shares outstanding: 51.66m
- Website: https://www.nuvasive.com
Number of Employees
- NuVasive, Inc.
- 7475 Lusk Boulevard
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/26 22:15|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.